Sign in
Taking people in United StatesPhase 1

Tests CTIM-76 in adults with recurring ovarian cancer and other solid tumors

Tests CTIM-76 in adults with advanced ovarian, testicular or endometrial cancer.

Key facts

Who runs it
Context Therapeutics Inc.
Where
Beverly Hills, Boston, Canton, Dallas, Denver, Durham, Hackensack, Little Rock, Nashville, New York, Omaha, Philadelphia, Portland, and Providence, United StatesSee the 14 sitesAlso in 3 other countries, 11 sites
Registry title
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Status
Recruiting
Phase
Phase 1
People taking part
156 people, planned
Started
10 Jul 2024
Expected to end
31 Dec 2028
Type of study
Interventional
Treatments tested
  • CTIM-76
Record updated
10 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with CLDN6-positive ovarian cancer that no longer responds to platinum treatment, or with advanced testicular or endometrial cancer. They must have disease that can be measured.

Age
18 years or older
Sex
All sexes can join
Disease stage
Platinum-resistant or platinum-refractory ovarian cancer, advanced testicular cancer, or advanced endometrial cancer, with measurable disease per RECIST 1.1
Biomarker or test result
The tumour must be CLDN6 positive

Main reasons for not taking part

  • Cancer spread to the brain or spinal cord, or leptomeningeal disease
  • Uncontrolled serious active infection
  • Any other condition the investigator thinks would prevent taking part
  • Taking part in another investigational trial at the same time

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Participants with CLDN6 positive platinum resistant/refractory ovarian, advanced testicular or advanced endometrial cancer
  • Participants with measurable disease per RECIST 1.1
  • ECOG 0, 1, or 2 and life expectancy of ≥ 12 weeks
  • Participants with adequate organ function

Who cannot take part

  • Concurrent participation in another investigational clinical trial
  • Evidence of central nervous system metastases, leptomeningeal disease or spinal cord compression
  • Uncontrolled significant active infection or any medical or other condition that in opinion of the Investigator would preclude the participant's participation in the study

Where in United States

Also in 3 other countries, 11 sites

  • Precision NextGen Oncology & Research CenterBeverly Hills, United StatesContact: Context Clinical DevelopmentNo longer taking part
  • Dana-Farber Cancer InstituteBoston, United StatesContact: Rebecca Porter, MDTaking people
  • Gabrail Cancer CenterCanton, United StatesContact: Context Clinical DevelopmentNo longer taking part
  • SCRI at Mary CrowleyDallas, United StatesContact: Angela HotchkissTaking people
  • SCRI at Denver HealthDenver, United StatesContact: Front DeskTaking people
  • Duke Cancer InstituteDurham, United StatesContact: Duke Cancer Institute - Phase I and Immunotherapy TrialsTaking people
  • John Theurer Cancer CenterHackensack, United StatesContact: Context Clinical DevelopmentNo longer taking part
  • University of Arkansas - Winthrop P. Rockefeller Cancer InstituteLittle Rock, United StatesContact: Maroof ZafarTaking people
  • Vanderbilt-Ingram Cancer CenterNashville, United StatesContact: Vanderbilt-Ingram Cancer Center Clinical Trials Office (CTO)Taking people
  • Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Roisin O'Cearbhaill, MDTaking people
  • University of Nebraska MedicalOmaha, United StatesContact: Marnee Strege, RN BSNTaking people
  • Fox Chase Cancer CenterPhiladelphia, United StatesContact: Context Clinical DevelopmentNo longer taking part
  • Providence Cancer Institute of OregonPortland, United StatesContact: Christopher Darus, MDTaking people
  • Women & Infants Hospital of Rhode IslandProvidence, United StatesContact: Mary DionneTaking people

About the trial

What the trial wants to find out

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).

The group in the trial

  • CTIM-76Treatment being tested

    Phase 1a: Dose Escalation-each dose cohort will assess toxicity 28 days following the first dose of CTIM76; anticipate a total of 9 dose cohorts. Phase 1b: Dose Expansion - approximately 80 participants will be evaluated at a minimum of 2 dose levels and/or dosing schedules of CTIM-76

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 1, First in Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Plain-language title
Tests CTIM-76 in adults with recurring ovarian cancer and other solid tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
10 November 2026